Research programme: bicycle peptide therapeutics - Bicycle Therapeutics

Drug Profile

Research programme: bicycle peptide therapeutics - Bicycle Therapeutics

Alternative Names: BT-1718

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Bicycle Therapeutics
  • Class Peptides; Small molecules
  • Mechanism of Action Kallikrein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Inflammation; Metabolic disorders

Most Recent Events

  • 15 Dec 2016 Bicycle Therapeutics and Cancer Research UK enter into an agreement to conduct phase Ia and phase Ib trials
  • 29 Nov 2016 Pharmacokinetic and Pharmacodynamic data from a preclinical study in Cancer presented at the 28th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Inflammation in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top